IL240735A0 - Stable glucokinase activator compounds - Google Patents

Stable glucokinase activator compounds

Info

Publication number
IL240735A0
IL240735A0 IL240735A IL24073515A IL240735A0 IL 240735 A0 IL240735 A0 IL 240735A0 IL 240735 A IL240735 A IL 240735A IL 24073515 A IL24073515 A IL 24073515A IL 240735 A0 IL240735 A0 IL 240735A0
Authority
IL
Israel
Prior art keywords
stable
glucokinase activator
activator compositions
compositions
glucokinase
Prior art date
Application number
IL240735A
Other languages
English (en)
Hebrew (he)
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of IL240735A0 publication Critical patent/IL240735A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL240735A 2013-03-04 2015-08-20 Stable glucokinase activator compounds IL240735A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772022P 2013-03-04 2013-03-04
PCT/US2014/019349 WO2014137797A2 (en) 2013-03-04 2014-02-28 Stable glucokinase activator compositions

Publications (1)

Publication Number Publication Date
IL240735A0 true IL240735A0 (en) 2015-10-29

Family

ID=50424705

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240735A IL240735A0 (en) 2013-03-04 2015-08-20 Stable glucokinase activator compounds

Country Status (11)

Country Link
US (1) US20160015638A1 (enExample)
EP (1) EP2964198A2 (enExample)
JP (1) JP6441828B2 (enExample)
KR (1) KR20150123838A (enExample)
CN (1) CN105050585A (enExample)
AU (1) AU2014226290B2 (enExample)
CA (1) CA2903433A1 (enExample)
HK (1) HK1213780A1 (enExample)
IL (1) IL240735A0 (enExample)
MX (1) MX2015011109A (enExample)
WO (1) WO2014137797A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012029844A2 (pt) 2010-05-26 2015-10-13 Transtech Pharma Inc uso de metamorfina em combinação com um ativador de glucoquinase e combinações compreendendo metamorfina com um ativador de glucoquinase
AU2013262895A1 (en) 2012-05-17 2014-11-13 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of diabetes
JP6913180B2 (ja) * 2016-12-15 2021-08-04 華領医薬技術(上海)有限公司Hua Medicine (Shanghai) Ltd. グルコキナーゼ活性化剤の経口製剤およびその製造方法
EP4487909A3 (en) 2018-06-12 2025-03-19 vTv Therapeutics LLC Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
WO2021243645A1 (en) * 2020-06-04 2021-12-09 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
US11857536B2 (en) 2020-06-04 2024-01-02 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
CA3181665A1 (en) * 2020-06-08 2021-12-16 Jing TENG Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof
EP4161640A4 (en) * 2020-06-08 2024-01-17 vTv Therapeutics LLC Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
KR20240084229A (ko) * 2022-12-06 2024-06-13 유노비아 주식회사 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
WO2003024425A1 (en) * 2001-09-19 2003-03-27 Elan Pharma International, Ltd. Nanoparticulate insulin formulations
EP1503737B1 (en) * 2002-05-06 2009-01-07 Elan Pharma International Limited Nanoparticulate nystatin formulations
EP1511467A1 (en) * 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
AU2003241478A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd. Nanoparticulate sterol formulations and sterol combinations
EP2444397A1 (en) * 2004-01-06 2012-04-25 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
CA2587710C (en) * 2004-11-16 2014-10-21 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
JP2008524239A (ja) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミティド ナノ粒子のタクロリムス製剤
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
CA2594332A1 (en) * 2005-01-06 2006-07-13 Elan Pharma International Ltd. Nanoparticulate candesartan formulations
EA015987B1 (ru) * 2005-02-24 2012-01-30 Элан Фарма Интернэшнл Лимитед Композиция для инъекций, содержащая наночастицы доцетаксела и стабилизатор поверхности
EP1865928A1 (en) * 2005-03-17 2007-12-19 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
BRPI0606282A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições injetáveis de compostos imunossupressores em nanopartìculas
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
AU2006336417A1 (en) * 2005-05-10 2007-08-02 Elan Pharma International, Limited Nanoparticulate clopidogrel formulations
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
EA015102B1 (ru) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Препараты наночастиц мезилата иматиниба
CN101262860A (zh) * 2005-06-03 2008-09-10 伊兰制药国际有限公司 纳米微粒对乙酰氨基酚制剂
WO2006135689A2 (en) * 2005-06-09 2006-12-21 Elan Pharma International, Limited Nanoparticulate ebastine formulations
US20070015719A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US20070281011A1 (en) * 2006-05-30 2007-12-06 Elan Pharma International Ltd. Nanoparticulate posaconazole formulations
AU2007325628A1 (en) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
US8163779B2 (en) * 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US20090028680A1 (en) * 2007-07-27 2009-01-29 Kling Troy L Intermediate apparatus for towing utility vehicles
PE20091901A1 (es) * 2008-05-16 2010-01-06 Takeda San Diego Inc Activadores de glucoquinasa
US8054567B2 (en) * 2008-07-23 2011-11-08 Hitachi High-Technologies Corporation Method for measuring write/read width of a composite magnetic head and a measuring device using the method
JP2012530704A (ja) * 2009-06-18 2012-12-06 アボット・ラボラトリーズ 安定なナノ粒子状薬物懸濁液
AU2010261509A1 (en) * 2009-06-19 2012-02-09 Nanoform Hungary Ltd. Nanoparticulate telmisartan compositions and process for the preparation thereof
CN101829061A (zh) * 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
BR112012029844A2 (pt) * 2010-05-26 2015-10-13 Transtech Pharma Inc uso de metamorfina em combinação com um ativador de glucoquinase e combinações compreendendo metamorfina com um ativador de glucoquinase

Also Published As

Publication number Publication date
JP6441828B2 (ja) 2018-12-19
CN105050585A (zh) 2015-11-11
JP2016513625A (ja) 2016-05-16
AU2014226290B2 (en) 2018-11-15
WO2014137797A2 (en) 2014-09-12
MX2015011109A (es) 2015-11-16
US20160015638A1 (en) 2016-01-21
HK1213780A1 (zh) 2016-07-15
CA2903433A1 (en) 2014-09-12
KR20150123838A (ko) 2015-11-04
WO2014137797A3 (en) 2014-10-30
AU2014226290A1 (en) 2015-10-08
EP2964198A2 (en) 2016-01-13

Similar Documents

Publication Publication Date Title
IL295091B1 (en) Solid solution mixtures
GB201304662D0 (en) Compositions
SG11201602596UA (en) Stabilized efinaconazole compositions
PL3065569T3 (pl) Kompozycja
PT3027750T (pt) Composição biocatalítica
GB201608461D0 (en) Compositions
IL240735A0 (en) Stable glucokinase activator compounds
EP3006525A4 (en) ASPHALT-URETHANE COMPOSITION
GB201319540D0 (en) Composition
GB201318489D0 (en) Composition
GB201320919D0 (en) Composition
GB201317388D0 (en) Composition
GB201320303D0 (en) Composition
GB201319538D0 (en) Composition
GB201306984D0 (en) Composition
GB201322772D0 (en) Composition
GB201317196D0 (en) Composition
GB201307622D0 (en) Composition
ZA201505650B (en) New compositions
GB201320962D0 (en) Compositions
GB201316463D0 (en) Novel compositions
GB201420672D0 (en) Composition
GB201308502D0 (en) Composition
GB201301774D0 (en) Composition
GB201318394D0 (en) Composition